{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008988","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.827604+00:00","generated_at":"2026-06-25T21:36:06.073761+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kodiak Sciences Q1 net loss $95.7M ($1.83/share); updates KSI-301 program after Ph2b/3 miss","bullets":["Net loss $95.7M ($1.83/share) vs $50.4M ($0.98/share) in Q1 2021.","R&D expenses $76.2M, up 89% YoY; G&A $19.6M, up 92% YoY; cash $671.7M.","KSI-301 Phase 2b/3 wet AMD missed primary endpoint; ongoing Phase 3 studies modified to reduce undertreatment risk.","BEACON top-line data expected August 2022; DAYLIGHT, GLEAM, GLIMMER data mid-2023.","Commercial manufacturing facility in Visp, Switzerland reached mechanical completion March 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008988","json":"https://secwatch.observer/filing/0000950170-22-008988.json","markdown":"https://secwatch.observer/filing/0000950170-22-008988.md","text":"https://secwatch.observer/filing/0000950170-22-008988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022008988/0000950170-22-008988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017022008988/kod-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:36:06.073761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}